Who is sponsoring NCT01811823?

NCT01811823 is sponsored by University of Witwatersrand, South Africa.

What drugs are being tested in NCT01811823?

Interventions in NCT01811823: Trivalent Inactivated Influenza Vaccine.

What condition does NCT01811823 study?

NCT01811823 studies Influenza, HIV, Tuberculosis.

Is NCT01811823 still recruiting?

NCT01811823 is currently completed. Last updated 5 September 2018.

Last reviewed 2018-09-05 · How we verify

NCT01811823: TIV_HIV_TB

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults

Completed Phase 4 Last updated 5 September 2018

What this trial tests

Phase 4 trial testing Trivalent Inactivated Influenza Vaccine in Influenza in 301 participants. Completed in 20 November 2014.

Timeline

31 March 2014

Primary endpoint
20 November 2014

20 November 2014

Quick facts

Lead sponsor	University of Witwatersrand, South Africa
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	301
Start date	31 March 2014
Primary completion	20 November 2014
Estimated completion	20 November 2014
Sites	1 location across South Africa

Drugs / interventions tested

Trivalent Inactivated Influenza Vaccine — full drug profile →

Conditions studied

Influenza — all drugs for Influenza →
HIV — all drugs for HIV →
Tuberculosis — all drugs for Tuberculosis →

Sponsor

University of Witwatersrand, South Africa

Who can join

Adults 18 to 55, any sex, with Influenza or HIV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, open-labelled study which will enrol 360 participants in four groups of 80 participants including: HIV-uninfected adults without evidence of TB; HIV-infected adults without any evidence of TB; HIV-uninfected adults with concurrent microbiologic confirmed TB, HIV-infected adults with concurrent microbiologic confirmed TB. Participants will receive the recommended seasonal 2013 un-adjuvanted Trivalent Influenza Vaccine (TIV). At 3 visits, blood will be collected for determination of immune responses. Objective: • To determine the effect of HIV-infection, tuberculosis (TB) and HIV-TB co-infection on immune responses

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Influenza

Currently open trials in the same condition.

NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
NCT07496450 — A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults · Phase 3 · recruiting
NCT07302256 — A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above · Phase 1 · recruiting
NCT07431840 — Immune Defense Protein Impact On Respiratory Immune Outcomes · NA · recruiting
NCT07485855 — Influenza Vaccination Strategy for Patients With Hematologic Malignancy · Phase 3 · recruiting

Other University of Witwatersrand, South Africa trials

Trials by the same sponsor.

NCT06821152 — Functional Performance and Acceptability Evaluation of the Miss Liberty Female Condom Compared to the FC2 Female Condom · NA · completed
NCT06955728 — A Clinical Trial on Safety in Pregnant Women and How Well the Infant is Protected Against RSV-associated Lower Respirato · Phase 4 · not yet recruiting
NCT06485154 — Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial · Phase 4 · active not recruiting
NCT06138600 — Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Car · Phase 3 · active not recruiting
NCT05846503 — iHEART-SA Intervention Study · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01811823 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Witwatersrand, South Africa
Last refreshed: 5 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01811823.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing